Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission
- PMID: 31590930
- DOI: 10.1016/j.semarthrit.2019.09.005
Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission
Abstract
Objectives: In patients with rheumatoid arthritis (RA), remission may be assessed by various composite measures. We assessed achievement of remission as defined by Boolean criteria, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and 28-joint Disease Activity Score using C-reactive protein (DAS28[CRP]) and determined the components that limit patients in SDAI, CDAI, or DAS28(CRP) remission from achieving Boolean remission.
Methods: The proportions of patients achieving Boolean, SDAI, CDAI, or DAS28(CRP) remission were calculated for 3 trials: PREMIER and OPTIMA in patients with early RA and DE019 in patients with established RA. At the first visit that remission was recorded during the first 52 weeks of the trial, the following were assessed: swollen/tender joint count at 28 and 66/68 joints, CRP, Patient's/Physician's Global Assessment (PGA/PhGA), SDAI, DAS28(CRP), and Health Assessment Questionnaire-Disability Index.
Results: The majority of patients (61-66%) who achieved SDAI or CDAI remission also attained Boolean remission. Although DAS28(CRP) remission was most frequently attained, 74-77% of patients in DAS28(CRP) remission did not achieve Boolean remission. Compared with patients in Boolean remission, patients in SDAI or CDAI remission but not Boolean remission had higher PGA scores, while patients with DAS28(CRP) remission but not Boolean remission had higher joint counts, and PGA and PhGA scores.
Conclusions: Differences in PGA limit patients in SDAI/CDAI remission from meeting the Boolean remission criteria, suggesting that these criteria otherwise can be used interchangeably. In contrast, patients in DAS28(CRP) remission are limited by differences in multiple disease activity measures from achieving Boolean remission.
Keywords: Anti-TNF; Boolean remission; CDAI; Disease activity; Rheumatoid arthritis; SDAI.
Copyright © 2019. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest DA has received grants and consulting fees from AbbVie, Janssen, Pfizer, and Roche and consulting fees from Amgen, Celgene, Eli Lilly, Merck, Novartis, Sandoz, Sanofi/Genzyme, and UCB. XW, SZ, SF, and KM are employees of AbbVie and may own stock/options. JS has received grants and consulting fees from AbbVie, AstraZeneca, Janssen, Eli Lilly, Merck Sharpe & Dohme, Pfizer, and Roche and consulting fees from Amgen, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO Pharma, Novartis-Sandoz, Samsung, Sanofi, and UCB.
Comment in
-
The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?Semin Arthritis Rheum. 2020 Aug;50(4):583-585. doi: 10.1016/j.semarthrit.2020.03.014. Epub 2020 May 19. Semin Arthritis Rheum. 2020. PMID: 32460149 No abstract available.
-
Attaining CDAI remission is the first gateway to attain Boolean remission.Semin Arthritis Rheum. 2020 Aug;50(4):624-626. doi: 10.1016/j.semarthrit.2020.05.006. Epub 2020 May 25. Semin Arthritis Rheum. 2020. PMID: 32502726 No abstract available.
-
Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.Semin Arthritis Rheum. 2020 Aug;50(4):643-644. doi: 10.1016/j.semarthrit.2020.03.022. Epub 2020 May 5. Semin Arthritis Rheum. 2020. PMID: 32504990 No abstract available.
Similar articles
-
Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.Int J Rheum Dis. 2018 Nov;21(11):1933-1939. doi: 10.1111/1756-185X.13110. Epub 2017 Jun 12. Int J Rheum Dis. 2018. PMID: 28608433
-
Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.Arthritis Rheum. 2011 Jan;63(1):43-52. doi: 10.1002/art.27740. Arthritis Rheum. 2011. PMID: 21204103 Clinical Trial.
-
Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.Arthritis Res Ther. 2018 Jan 16;20(1):8. doi: 10.1186/s13075-017-1484-9. Arthritis Res Ther. 2018. PMID: 29338762 Free PMC article. Clinical Trial.
-
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.RMD Open. 2023 Apr;9(2):e003196. doi: 10.1136/rmdopen-2023-003196. RMD Open. 2023. PMID: 37116986 Free PMC article.
-
Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis.Rheumatology (Oxford). 2023 Apr 3;62(4):1410-1416. doi: 10.1093/rheumatology/keac515. Rheumatology (Oxford). 2023. PMID: 36125185
Cited by
-
A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry.Rheumatol Ther. 2024 Jun;11(3):709-736. doi: 10.1007/s40744-024-00668-z. Epub 2024 Apr 18. Rheumatol Ther. 2024. PMID: 38637465 Free PMC article.
-
Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.Rheumatol Int. 2023 Oct;43(10):1821-1828. doi: 10.1007/s00296-023-05349-8. Epub 2023 Jun 3. Rheumatol Int. 2023. PMID: 37269430
-
Remission or Not Remission, That's the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis.Rheumatol Ther. 2022 Dec;9(6):1531-1547. doi: 10.1007/s40744-022-00490-5. Epub 2022 Sep 21. Rheumatol Ther. 2022. PMID: 36129667 Free PMC article.
-
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study.Reumatologia. 2024;62(5):322-329. doi: 10.5114/reum/194686. Epub 2024 Nov 9. Reumatologia. 2024. PMID: 39677878 Free PMC article.
-
Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort.Arthritis Res Ther. 2024 Jan 9;26(1):16. doi: 10.1186/s13075-023-03251-z. Arthritis Res Ther. 2024. PMID: 38195572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous